Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

IMPORTANCE: Biosimilar drugs are potentially lower-cost versions of biologics that may improve access to therapy. However, there is a lack of adequate systematic reviews demonstrating equivalence between these drugs for the treatment of rheumatoid arthritis (RA). OBJECTIVES: To assess the efficacy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascef, Bruna de Oliveira, Almeida, Matheus Oliveira, de Medeiros-Ribeiro, Ana Cristina, Oliveira de Andrade, Danieli Castro, de Oliveira Junior, Haliton Alves, de Soárez, Patrícia Coelho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220520/
https://www.ncbi.nlm.nih.gov/pubmed/37234004
http://dx.doi.org/10.1001/jamanetworkopen.2023.15872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220520/
https://www.ncbi.nlm.nih.gov/pubmed/37234004
http://dx.doi.org/10.1001/jamanetworkopen.2023.15872

Ejemplares similares